Carderock Capital Management Inc. Buys 1,581 Shares of Eli Lilly and Company $LLY

Key Points

• Carderock Capital Management Inc. increased its stake in Eli Lilly and Company by 16.7%, acquiring an additional 1,581 shares during the second quarter, bringing its total holdings to 11,041 shares valued at approximately $8.6 million.
• Eli Lilly reported a 37.6% year-over-year increase in revenue to $15.56 billion and a quarterly EPS of $6.31, exceeding analysts' expectations.
• The company's recent quarterly dividend of $1.50 represents an annual yield of 0.8% and reflects a payout ratio of 39.22%.

Carderock Capital Management Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 16.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,041 shares of the company's stock after purchasing an additional 1,581 shares during the period. Eli Lilly and Company accounts for about 2.2% of Carderock Capital Management Inc.'s holdings, making the stock its 18th biggest position. Carderock Capital Management Inc.'s holdings in Eli Lilly and Company were worth $8,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently modified their holdings of the company. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $27,000. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the 1st quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at $43,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.3%

NYSE:LLY traded up $2.45 during trading hours on Monday, reaching $754.44. The company's stock had a trading volume of 1,704,044 shares, compared to its average volume of 4,092,634. The company has a market cap of $714.05 billion, a price-to-earnings ratio of 49.33, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.30. The business's 50-day moving average is $738.37 and its 200-day moving average is $769.80. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business earned $3.92 EPS. The firm's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock worth $2,894,841 in the last three months. 0.14% of the stock is owned by insiders.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. JPMorgan Chase & Co. cut their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a report on Tuesday, September 16th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.